CoChat

Targeted protein degradation mechanisms

Zhang, Yi, Loh, Christine, Chen, Jesse, Mainolfi, Nello · 2019 · Drug Discovery Today: Technologies
Cited by 45

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Targeted protein degradation mediated by small molecule degraders represents an exciting new therapeutic opportunity to eliminate disease-causing proteins. These molecules recruit E3 ubiquitin ligases to the protein of interest and mediate its ubiquitination and subsequent proteolysis by the proteasome. Significant advancements have been made in the discovery and development of clinically relevant degraders. In this review we will focus on the recent progress in understanding ternary complex formation and structures, ubiquitination, and other critical factors that govern the efficiency of degraders both in vitro and in vivo. With deeper knowledges of these areas, the field is building guiding principles to reduce the level of empiricism and to identify therapeutically relevant degraders more rationally and efficiently.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ddtec.2019.01.001

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 20

  1. Steinebach, 2018, Homo-PROTACs for the chemical knockdown of cereblon, ACS Chem Biol, 13, 2771, 10.1021/acschembio.8b00693 · DOI · Paper page
  2. Mainolfi, 2017, Targeted protein degradation, Annu Rep Med Chem, 50, 301
  3. Tinworth, 2016, Small molecule-mediated protein knockdown as a new approach to drug discovery, Medchemcomm, 7, 2206, 10.1039/C6MD00347H · DOI · Paper page
  4. Cromm, 2017, Targeted protein degradation: from chemical biology to drug discovery, Cell Chem Biol, 24, 1181, 10.1016/j.chembiol.2017.05.024 · DOI · Paper page
  5. Riching, 2018, Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action, ACS Chem Biol, 13, 2758, 10.1021/acschembio.8b00692 · DOI · Paper page
  6. Chan, 2018, Impact of target warhead and linkage vector on inducing protein degradation: comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds, J Med Chem, 61, 504, 10.1021/acs.jmedchem.6b01912 · DOI · Paper page
  7. Collins, 2017, Chemical approaches to targeted protein degradation through modulation of the ubiquitin–proteasome pathway, Biochem J, 474, 1127, 10.1042/BCJ20160762 · DOI · Paper page
  8. Remillard, 2017, Degradation of the BAF complex factor BRD9 by heterobifunctional ligands, Angew Chem Int Ed Engl, 56, 5738, 10.1002/anie.201611281 · DOI · Paper page
  9. Schiedel, 2018, Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals), J Med Chem, 61, 482, 10.1021/acs.jmedchem.6b01872 · DOI · Paper page
  10. Cesare, 2018, The MALDI-TOF E2/E3 ligase assay as universal tool for drug discovery in the ubiquitin pathway, Cell Chem Biol, 20, 1117, 10.1016/j.chembiol.2018.06.004 · DOI
  11. Kirkpatrick, 2005, The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications, Methods, 35, 265, 10.1016/j.ymeth.2004.08.018 · DOI · Paper page
  12. Grice, 2016, The recognition of ubiquitinated proteins by the proteasome, Cell Mol Life Sci, 73, 3497, 10.1007/s00018-016-2255-5 · DOI · Paper page
  13. Bustos, 2012, Characterizing ubiquitination sites by peptide-based immunoaffinity enrichment, Mol Cell Proteomics, 11, 1529, 10.1074/mcp.R112.019117 · DOI
  14. McDowell, 2013, Non-canonical ubiquitylation: mechanisms and consequences, J Int Biochem Cell Biol, 45, 1833, 10.1016/j.biocel.2013.05.026 · DOI · Paper page
  15. Xu, 2010, Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling, Nat Biotechnol, 28, 868, 10.1038/nbt.1654 · DOI · Paper page
  16. Akutsu, 2016, Ubiquitin chain diversity at a glance, J Cell Sci, 129, 875, 10.1242/jcs.183954 · DOI · Paper page
  17. Harris, 2015, Protein detection by Simple Western™ analysis, Methods Mol Biol, 1312, 465, 10.1007/978-1-4939-2694-7_47 · DOI
  18. Schulze, 2014, Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4, J Biomol Screen, 20, 180, 10.1177/1087057114552398 · DOI
  19. Savitski, 2018, Multiplexed proteome dynamics profiling reveals mechanisms controlling protein homeostasis, Cell, 173, 260, 10.1016/j.cell.2018.02.030 · DOI · Paper page
  20. Zhang, 2017, Relative protein quantification using tandem mass tag mass spectrometry, Proteomics, 1550, 185, 10.1007/978-1-4939-6747-6_14 · DOI

Cited by

Metadata

Authors
Zhang, Y., Loh, C., Chen, J., & Mainolfi, N.
Venue
Drug Discovery Today: Technologies
Publisher
Elsevier BV
Published
2019-04
Volume
31
Pages
53-60
ISSN
1740-6749 (ISSN-L)
OpenAlex
W2911917285
Cited by
45
References
19
FWCI
2.22
Type
journal article
Language
en
Update notices
erratum (2020-12-01)
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.